AREDIA Drug Patent Profile
✉ Email this page to a colleague
When do Aredia patents expire, and what generic alternatives are available?
Aredia is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in AREDIA is pamidronate disodium. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pamidronate disodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aredia
A generic version of AREDIA was approved as pamidronate disodium by HIKMA on April 30th, 2001.
Summary for AREDIA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 85 |
| Clinical Trials: | 12 |
| Patent Applications: | 3,829 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | AREDIA at DailyMed |
Recent Clinical Trials for AREDIA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ottawa Hospital Research Institute | Phase 4 |
| Masonic Cancer Center, University of Minnesota | Phase 2 |
| Amgen | Phase 4 |
US Patents and Regulatory Information for AREDIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-001 | Oct 31, 1991 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-003 | May 6, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-004 | May 6, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AREDIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-004 | May 6, 1993 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-003 | May 6, 1993 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-001 | Oct 31, 1991 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-003 | May 6, 1993 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-004 | May 6, 1993 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AREDIA
See the table below for patents covering AREDIA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Philippines | 24854 | NOVEL CRYSTAL MODIFICATION OF DISODIUM 3-AMINO-1-HYDROXYPROPANE-1,1-DIPHOSPHONATE | ⤷ Try a Trial |
| Canada | 1255694 | MODIFICATION CRISTALLINE DE 3-AMINO-1- HYDROXYPROPANE-1,1-DIPHOSPHONATE DISODIQUE (CRYSTAL MODIFICATION OF DISODIUM 3-AMINO-1- HYDROXYPROPANE-1,1-DIPHOSPHONATE) | ⤷ Try a Trial |
| Australia | 591066 | ⤷ Try a Trial | |
| France | 2259615 | ⤷ Try a Trial | |
| Germany | 2405254 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
